StockMacro
Menu

Sotera Health

$15.91 -0.3% in 6 monthsMarket cap $4.5B

SHC on XNAS, Health Care, Sotera Health Company, job postings

Measures activity, not value. Not investment advice.

Net income up 213% to $173.5M on 6.9% revenue growth, while shares fell 10% in a month.

  • GoodInstitutional holders rose 9.2% to 344 from 315 in the quarter before
  • WatchCapital spending up 46% to $52.8M from $36.2M a year earlier

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.

Industry
Services-misc health & allied services, nec (Health Care)
Employees
3,000
Website
soterahealth.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $324.9M, net income $58.4M.
Quarter to 31 Dec 2021: revenue $241.2M, net income $36.0MQuarter to 31 Dec 2021: revenue $241.2M, net income $36.0MQuarter to 31 Mar 2022: revenue $236.8M, net income $30.6MQuarter to 31 Mar 2022: revenue $236.8M, net income $30.6MQuarter to 30 Jun 2022: revenue $266.6M, net income $30.4MQuarter to 30 Jun 2022: revenue $266.6M, net income $30.4MQuarter to 30 Sep 2022: revenue $248.7M, net income $25.1MQuarter to 30 Sep 2022: revenue $248.7M, net income $25.1MQuarter to 31 Dec 2022: revenue $251.6M, net income -$319.7MQuarter to 31 Dec 2022: revenue $251.6M, net income -$319.7MQuarter to 31 Mar 2023: revenue $220.6M, net income $2.8MQuarter to 31 Mar 2023: revenue $220.6M, net income $2.8MQuarter to 30 Jun 2023: revenue $255.3M, net income $23.5MQuarter to 30 Jun 2023: revenue $255.3M, net income $23.5MQuarter to 30 Sep 2023: revenue $263.2M, net income -$13.7MQuarter to 30 Sep 2023: revenue $263.2M, net income -$13.7MQuarter to 31 Dec 2023: revenue $310.2M, net income $38.7MQuarter to 31 Dec 2023: revenue $310.2M, net income $38.7MQuarter to 31 Mar 2024: revenue $248.2M, net income $6.3MQuarter to 31 Mar 2024: revenue $248.2M, net income $6.3MQuarter to 30 Jun 2024: revenue $276.6M, net income $8.8MQuarter to 30 Jun 2024: revenue $276.6M, net income $8.8MQuarter to 30 Sep 2024: revenue $285.5M, net income $17.0MQuarter to 30 Sep 2024: revenue $285.5M, net income $17.0MQuarter to 31 Dec 2024: revenue $290.2M, net income $12.3MQuarter to 31 Dec 2024: revenue $290.2M, net income $12.3MQuarter to 31 Mar 2025: revenue $254.5M, net income -$13.3MQuarter to 31 Mar 2025: revenue $254.5M, net income -$13.3MQuarter to 30 Jun 2025: revenue $294.3M, net income $8.0MQuarter to 30 Jun 2025: revenue $294.3M, net income $8.0MQuarter to 30 Sep 2025: revenue $311.3M, net income $48.4MQuarter to 30 Sep 2025: revenue $311.3M, net income $48.4MQuarter to 31 Dec 2025: revenue $303.4M, net income $34.8MQuarter to 31 Dec 2025: revenue $303.4M, net income $34.8MQuarter to 31 Mar 2026: revenue $280.0M, net income $26.6MQuarter to 31 Mar 2026: revenue $280.0M, net income $26.6MQuarter to 30 Jun 2026: revenue $321.4M, net income $53.6MQuarter to 30 Jun 2026: revenue $321.4M, net income $53.6MQuarter to 30 Sep 2026: revenue $324.9M, net income $58.4MQuarter to 30 Sep 2026: revenue $324.9M, net income $58.4M
31 Dec 2021RevenueNet incomeNet losstallest bar $324.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$324.9M$58.4M
30 Jun 2026$321.4M$53.6M
31 Mar 2026$280.0M$26.6M
31 Dec 2025$303.4M$34.8M
30 Sep 2025$311.3M$48.4M
30 Jun 2025$294.3M$8.0M
31 Mar 2025$254.5M-$13.3M
31 Dec 2024$290.2M$12.3M
30 Sep 2024$285.5M$17.0M
30 Jun 2024$276.6M$8.8M
31 Mar 2024$248.2M$6.3M
31 Dec 2023$310.2M$38.7M
30 Sep 2023$263.2M-$13.7M
30 Jun 2023$255.3M$23.5M
31 Mar 2023$220.6M$2.8M
31 Dec 2022$251.6M-$319.7M
30 Sep 2022$248.7M$25.1M
30 Jun 2022$266.6M$30.4M
31 Mar 2022$236.8M$30.6M
31 Dec 2021$241.2M$36.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.2B $1.2B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +6.9% +3.8%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $173.5M $55.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.60 $0.20
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 54.6% 56.0% 56.0%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – 7.8%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 14.1% 4.8% 5.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 27.0% -9.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $135.4M $86.6M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $412.4M $299.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $2.1B $2.1B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $1.7B $1.8B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 2.9 0.06
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.57
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 26.2 24.7
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.7 1.1
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 5.1 1.2
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.2 4.1

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Sotera HealthSHC (this company) $4.5B26.23.7+6.9%14.1%
ProgynyPGNY $2.6B28.92.0+5.5%6.8%
DaVitaDVA $10.1B11.00.71+6.4%6.5%
agilon healthAGL $1.5Bloss0.25+2.0%-1.5%
Viemed HealthcareVMD $322.8M20.71.0+22%5.0%
Adaptive BiotechnologiesADPT $4.5Bloss15.2+18%-23.7%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.2%

344 13F filers vs 315

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

97%

278.0M shares held by 13F filers (30 Sep 2026) of 285.6M outstanding (27 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.8%

16.4M shares sold short (30 Oct 2026) of 285.6M outstanding (27 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.5

16.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+2.1%

16.1M shares sold short in the report before, 16.4M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

61%

61% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 59%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+4.4%

$324.9M vs $311.3M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+46%

$52.8M vs $36.2M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

10

10 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

10×

10 articles in the last 7 days; its usual week has 1.

Price $15.91 on 20 Nov 2026, +0.8% over 12 months (12-month range $13.13 to $19.57)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
Insider net buying (open market). Insiders sold a net $1.2B in the last 12 months (the 12 months before: -$773.8M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $324.9M in the latest quarter, +4.4% on a year earlier.
Capital spending per quarter. Capital spending $52.8M in the latest quarter, +46% on a year earlier.
Institutional holders (13F filers). 344 13F filers reported holding it in the latest 13F quarter, +48% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.
Lobbying spend. Lobbying spend: $0 published in the last 12 months.
Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
14 Aug 20268-K and other filingsDirector or officer change
14 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 May 20268-K and other filingsA major agreement ended
5 May 20268-K and other filingsDirector or officer change
16 Mar 20268-K and other filingsDirector or officer change
24 Feb 20268-K and other filingsDirector or officer change
5 Feb 20268-K and other filingsDirector or officer change
5 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 46 vs usual 25 (2025-06-30); 1.3x the same period a year earlier
6 Sep 20248-K and other filingsDirector or officer change
1 Aug 20248-K and other filingsDirector or officer change
1 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 May 20248-K and other filingsA major agreement ended
13 Nov 20238-K and other filingsDirector or officer change
13 Nov 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Jun 20238-K and other filingsDirector or officer change
26 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Mar 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 71.7M vs usual 29.7M (2022-12-31); 1.7x the same period a year earlier
1 Feb 2023WARN layoff noticeNelson Laboratories LLC, 66 workers, Fairfield, NJ
1 Feb 2023Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 66)
9 Nov 20228-K and other filingsDirector or officer change
13 Oct 20228-K and other filingsDirector or officer change
6 Sep 20228-K and other filingsDirector or officer change
16 Aug 2022Sharp changeShort interest spike: short interest spike, 6.1M vs usual 3.1M (2022-07-29); 2.3x the same period a year earlier
20 Jul 20228-K and other filingsDirector or officer change
19 Jul 2022Sharp changeShort interest spike: short interest spike, 5.9M vs usual 3.1M (2022-06-30); 1.6x the same period a year earlier
19 May 20228-K and other filingsDirector or officer change
19 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 41.3M vs usual 16.1M (2021-12-31); 2.1x the same period a year earlier
Insider net buying (open market)
Month from 1 Mar 2024: -$411.4M published
Month from 1 Sep 2024: -$375.8M published
Month from 1 Aug 2025: -$2.1M published
Month from 1 Sep 2025: -$302.2M published
Month from 1 Nov 2025: -$469.5M published
Month from 1 Dec 2025: -$276.9M published
Month from 1 Mar 2026: -$381.8M published
Month from 1 May 2026: -$483.0M published
Month from 1 Aug 2026: -$24.0M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Jul 2025: 1 published
Revenue per quarter
Quarter ended 31 Dec 2020: $216.8M; public on 2 Mar 2022
Quarter ended 31 Dec 2021: $241.2M, +11% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $236.8M, +12% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $266.6M, +5.8% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $248.7M, +10% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $251.6M, +4.3% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $220.6M, -6.8% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $255.3M, -4.3% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $263.2M, +5.8% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $310.2M, +23% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $248.2M, +13% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $276.6M, +8.3% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $285.5M, +8.5% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $290.2M, -6.5% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $254.5M, +2.6% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $294.3M, +6.4% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $311.3M, +9.1% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $303.4M, +4.6% on a year earlier; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $280.0M, +10% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $321.4M, +9.2% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $324.9M, +4.4% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $19.9M; public on 2 Mar 2022
Quarter ended 31 Dec 2021: $41.3M, +108% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $35.5M, +70% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $36.1M, +51% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $39.0M, +142% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $71.7M, +74% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $45.0M, +27% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $53.1M, +47% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $52.0M, +33% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $64.8M, -9.6% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $34.9M, -22% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $41.9M, -21% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $36.4M, -30% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $65.9M, +1.6% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $19.9M, -43% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $31.2M, -26% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $36.2M, -0.6% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $50.7M, -23% on a year earlier; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $46.2M, +132% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $46.4M, +49% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $52.8M, +46% on a year earlier; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 139; public on 14 Feb 2022
31 Mar 2022 report: 143; public on 16 May 2022
30 Jun 2022 report: 171; public on 15 Aug 2022
30 Sep 2022 report: 172; public on 14 Nov 2022
31 Dec 2022 report: 161; public on 14 Feb 2023
31 Mar 2023 report: 172; public on 15 May 2023
30 Jun 2023 report: 165; public on 14 Aug 2023
30 Sep 2023 report: 160; public on 14 Nov 2023
31 Dec 2023 report: 170; public on 14 Feb 2024
31 Mar 2024 report: 189; public on 15 May 2024
30 Jun 2024 report: 196; public on 14 Aug 2024
30 Sep 2024 report: 200; public on 14 Nov 2024
31 Dec 2024 report: 214; public on 14 Feb 2025
31 Mar 2025 report: 196; public on 15 May 2025
30 Jun 2025 report: 218; public on 14 Aug 2025
30 Sep 2025 report: 233; public on 14 Nov 2025
31 Dec 2025 report: 272; public on 17 Feb 2026
31 Mar 2026 report: 290; public on 15 May 2026
30 Jun 2026 report: 315; public on 14 Aug 2026
30 Sep 2026 report: 344; public on 16 Nov 2026
Federal obligations
Month from 1 May 2024: -$110K published
Lobbying spend
Quarter from 1 Apr 2022: $10K published
Workers in WARN layoff notices
Month from 1 Feb 2023: 66 published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is workers named in WARN notices at 66 (26 Dec 2022), 1.8× its normal reading.
  • Insider net buying (open market): Insiders sold a net $1.2B in the last 12 months (the 12 months before: -$773.8M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
  • Revenue per quarter: Revenue $324.9M in the latest quarter, +4.4% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 34 insider trades

No trades in the last 90 days; the latest was filed 19 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Aug 2026Michael B. Petras Jr.Executive ChairmanSell1,144,515$18.50$21.2MForm 4
11 Aug 2026Michael P RutzPresident of SterigenicsSell150,000$18.84$2.8MForm 4
15 May 2026GTCR Fund Xi/C LP and 4 othersDirector, 10% ownerSell12,735,301$15.17$193.2MForm 4
15 May 2026Warburg Pincus XI, L.P. and 9 othersDirector, 10% ownerSell19,102,952$15.17$289.8MForm 4
10 Mar 2026Warburg Pincus Partners II, L.P. and 9 othersDirector, 10% ownerSell15,000,000$15.27$229.1MForm 4
10 Mar 2026GTCR Co-Invest Xi LP and 4 othersDirector, 10% ownerSell10,000,000$15.27$152.7MForm 4
10 Dec 2025Michael B. Petras Jr.Chairman & CEOSell750,000$16.45$12.3MForm 4
5 Dec 2025Warburg Pincus Partners GP LLC and 7 othersDirector, 10% ownerSell9,720,000$16.33$158.7MForm 4

344 institutions reported shares at the end of Q3 2026, 97% of the shares outstanding; 65 opened a position, 30 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Sessa Capital IM, L.P.27.1M9.47%$500.2MNo change
Darsana Capital Partners LP27.0M9.45%$499.2MNo change
BlackRock, Inc.25.8M9.03%$476.7M+1.6M+6.8%
Sculptor Capital LP23.0M8.05%$425.3M-1.0M-4.2%
AQR Capital Management LLC13.2M4.62%$243.8M+2.4M+23%
Vanguard Capital Management LLC12.4M4.34%$229.1M+219K+1.8%
Vanguard Portfolio Management LLC11.7M4.11%$217.2M-201K-1.7%
T. Rowe Price Investment Management, Inc.10.4M3.64%-115K-1.1%
State Street Corp8.7M3.06%$161.7M+421K+5.1%
Janus Henderson Group Ltd.7.8M2.73%$144.1M

Company events

All 35 company events

In 12 months: 5 director or officer changes, 1 agreement ended, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
14 Aug 2026Director or officer change8-K
20 May 2026Signed a major agreementSame filing: took on new debt8-K
13 May 2026A major agreement ended8-K
5 May 2026Director or officer change8-K
16 Mar 2026Director or officer change8-K
24 Feb 2026Director or officer change8-K
5 Feb 2026Director or officer change8-K
18 Sep 2025Signed a major agreementSame filing: took on new debt8-K

Reported lobbying spend: $10K in Q1 2022, $20K in Q3 2021. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Mar 2020NewVan Ness Feldman, LLPfor Nordion, Inc. (Fka Nordion (Canada), Inc.)All Congressional and Executive branch actions, legislation and policies related to: the production, supply and distribution of Cobalt-60; gamma irradiation; sanctions on Iran and Russia; and COVID-19 response.FOR, Energy, Health issuesFiling
15 Jul 2018EndedVan Ness Feldman, LLPfor Nordion (Canada) IncAll Congressional and administrative actions related to the regulation and management of nuclear and radioactive materials; the production and sale of radioisotopes; the Nuclear Regulatory Commission; the National Nuclear Safety Administration. All Congressional activity related to sanctions on RussWAS, FOR, EnergyFiling
1 Jan 2018EndedPaul Grayfor Nordion (Canada), Inc.Not statedFiling
29 Jun 2017NewVan Ness Feldman, LLPfor Nordion (Canada) IncAll Congressional and administrative actions related to the regulation and management of nuclear and radioactive materials; the production and sale of radioisotopes; the Nuclear Regulatory Commission; the National Nuclear Safety Administration. All Congressional activity related to sanctions on RussWAS, Energy, FORFiling
14 Apr 2017NewPaul Grayfor Nordion (Canada), Inc.All legislative matters related to the regulation and management of nuclear and radioactive materials; Nuclear Regulatory Commission; National Nuclear Safety Administration; and Russian sanctions legislationWAS, Energy, FORFiling
31 Jan 2017EndedQorvis Communications LLC (Formerly Mslgroup Americas, Inc., D/B/A Qorvis Mslgroup)for Paa Public Affairs Advisors (On Behalf Of Sterigenics LLC)Not statedFiling
5 Dec 2016NewVan Ness Feldman, LLPfor SterigenicsIssues related to contract sterilization, including gamma irradiation and cobalt 60.EnergyFiling
1 Feb 2016NewQorvis Communications LLC (Formerly Mslgroup Americas, Inc., D/B/A Qorvis Mslgroup)for Paa Public Affairs Advisors (On Behalf Of Sterigenics LLC)Use of gamma sterilization in the health care and food safety industries; Legislative and regulatory oversight of the use of gamma irradiation as a means of sterilizing medical devices, health care products and food.FOO, Health issues, Budget, EnergyFiling

Layoff notices

All 2 layoff notices

No notice in 12 months; the latest is dated 1 Jan 2023. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Jan 2023Nelson Laboratories LLCFairfield, NJ6628 Apr 2023Notice
30 Sep 2019SterigenicsDu Page County, IL371 Sep 2019layoffNotice

The 5 newest of 84 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

22 Oct 2019confirmed

Confirmed across sources Layoff notices and Lobbying

Sotera Health (SHC): filed a WARN layoff notice covering 37 workers within 30 days, while it reported $150K of lobbying spend for the quarter ended 30 Sep 2019, 2.1× the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Layoff notices: WARN layoff notice, became public on 1 Oct 2019
  • Lobbying: Lobbying spend jump, became public on 17 Oct 2019
2017-09-30: $60K2017-12-31: $60K2018-03-31: $60K2018-06-30: $60K2018-09-30: $70K2018-12-31: $60K2019-03-31: $125K2019-06-30: $145K2019-09-30: $150K
The quarter ended 30 Sep 2019 against the 8 quarters before it. this quarterearliernormal: $60K
See the evidence (2 changes)

Layoff notices: WARN layoff notice became public on 1 Oct 2019

Sotera Health filed a WARN layoff notice covering 37 workers within 30 days.

Notices in the window
1
Workers named
37
Window
1 Sep 2019 to 1 Oct 2019

Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

Lobbying: Lobbying spend jump became public on 17 Oct 2019

Sotera Health reported $150K of lobbying spend for the quarter ended 30 Sep 2019, 2.1× the same quarter last year.

This period
$150K (the quarter ended 30 Sep 2019)
Normal quarter (median of 8 earlier)
$60K
Typical spread (median absolute deviation)
$0
How far from its usual level
+4.5
Same quarter last year
$70K
History used
1,278 days
2017-09-30: $60K2017-12-31: $60K2018-03-31: $60K2018-06-30: $60K2018-09-30: $70K2018-12-31: $60K2019-03-31: $125K2019-06-30: $145K2019-09-30: $150K
the quarter ended 30 Sep 20198 earlier quartersnormal: $60K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 14 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 14 Aug 2026Filings record

    Director or officer change

  3. 13 May 2026Filings record

    A major agreement ended

  4. 5 May 2026Filings record

    Director or officer change

  5. 16 Mar 2026Filings record

    Director or officer change

  6. 24 Feb 2026Filings record

    Director or officer change

  7. 5 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 5 Feb 2026Filings record

    Director or officer change

  9. 14 Aug 2025Institutional holdings change

    saw 46 13F filers open a new position in the quarter ended 30 Jun 2025, 1.3× the same quarter last year.

    Same quarter last year: 35; its normal quarter is 25.

    See the evidence
    This period
    46 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    25
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +3.5
    Same quarter last year
    35
    History used
    1,642 days
    2023-06-30: 232023-09-30: 162023-12-31: 202024-03-31: 362024-06-30: 352024-09-30: 262024-12-31: 282025-03-31: 242025-06-30: 46
    the quarter ended 30 Jun 20258 earlier quartersnormal: 25

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  10. 6 Sep 2024Filings record

    Director or officer change

  11. 1 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 1 Aug 2024Filings record

    Director or officer change

  13. 30 May 2024Filings record

    A major agreement ended

  14. 13 Nov 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 13 Nov 2023Filings record

    Director or officer change

  16. 26 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 26 Jun 2023Filings record

    Director or officer change

  18. 7 Mar 2023Financials change

    spent $71.7M on capital projects in the quarter ended 31 Dec 2022, 1.7× the same quarter last year.

    Same quarter last year: $41.3M; its normal quarter is $29.7M.

    See the evidence
    This period
    $71.7M (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    $29.7M
    Typical spread (median absolute deviation)
    $9.0M
    How far from its usual level
    +3.1
    Same quarter last year
    $41.3M
    History used
    1,005 days
    2020-12-31: $19.9M2021-03-31: $20.9M2021-06-30: $23.8M2021-09-30: $16.1M2021-12-31: $41.3M2022-03-31: $35.5M2022-06-30: $36.1M2022-09-30: $39.0M2022-12-31: $71.7M
    the quarter ended 31 Dec 20228 earlier quartersnormal: $29.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  19. 1 Feb 2023Layoff notices change

    filed a WARN layoff notice covering 66 workers within 30 days (Fairfield, NJ).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    66
    Window
    2 Jan 2023 to 1 Feb 2023

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  20. 1 Feb 2023Layoff notices record

    WARN notice: Nelson Laboratories LLC, 66 workers, Fairfield, NJ (dated 1 Jan 2023)

  21. 9 Nov 2022Filings record

    Director or officer change

  22. 13 Oct 2022Filings record

    Director or officer change

  23. 6 Sep 2022Filings record

    Director or officer change

  24. 10 Aug 2022Short interest and volume change

    had 6.1M shares sold short in the 29 Jul 2022 report, 2.3× the same report last year.

    Same report last year: 2.7M; its normal report is 3.1M.

    See the evidence
    This period
    6.1M (the 29 Jul 2022 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    553K
    How far from its usual level
    +3.6
    Same report last year
    2.7M
    History used
    606 days
    2021-07-15: 3.0M2021-07-30: 2.7M2021-08-13: 2.0M2021-08-31: 2.1M2021-09-15: 1.8M2021-09-30: 2.4M2021-10-15: 2.8M2021-10-29: 2.8M2021-11-15: 3.0M2021-11-30: 2.7M2021-12-15: 3.1M2022-01-14: 3.4M2022-01-31: 3.1M2022-02-15: 4.6M2022-02-28: 4.5M2022-03-15: 5.0M2022-03-31: 4.1M2022-04-14: 4.1M2022-04-29: 4.2M2022-05-13: 3.1M2022-05-31: 3.3M2022-06-15: 3.1M2022-06-30: 5.9M2022-07-15: 5.3M2022-07-29: 6.1M
    the 29 Jul 2022 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 20 Jul 2022Filings record

    Director or officer change

  26. 13 Jul 2022Short interest and volume change

    had 5.9M shares sold short in the 30 Jun 2022 report, 1.6× the same report last year.

    Same report last year: 3.6M; its normal report is 3.1M.

    See the evidence
    This period
    5.9M (the 30 Jun 2022 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    464K
    How far from its usual level
    +4.1
    Same report last year
    3.6M
    History used
    577 days
    2021-06-15: 2.1M2021-06-30: 3.6M2021-07-15: 3.0M2021-07-30: 2.7M2021-08-13: 2.0M2021-08-31: 2.1M2021-09-15: 1.8M2021-09-30: 2.4M2021-10-15: 2.8M2021-10-29: 2.8M2021-11-15: 3.0M2021-11-30: 2.7M2021-12-15: 3.1M2022-01-14: 3.4M2022-01-31: 3.1M2022-02-15: 4.6M2022-02-28: 4.5M2022-03-15: 5.0M2022-03-31: 4.1M2022-04-14: 4.1M2022-04-29: 4.2M2022-05-13: 3.1M2022-05-31: 3.3M2022-06-15: 3.1M2022-06-30: 5.9M
    the 30 Jun 2022 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 19 May 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 19 May 2022Filings record

    Director or officer change

  29. 8 Mar 2022Financials change

    spent $41.3M on capital projects in the quarter ended 31 Dec 2021, 2.1× the same quarter last year.

    Same quarter last year: $19.9M; its normal quarter is $16.1M.

    See the evidence
    This period
    $41.3M (the quarter ended 31 Dec 2021)
    Normal quarter (median of 7 earlier)
    $16.1M
    Typical spread (median absolute deviation)
    $4.8M
    How far from its usual level
    +3.5
    Same quarter last year
    $19.9M
    History used
    640 days
    2020-03-31: $13.0M2020-06-30: $10.4M2020-09-30: $10.2M2020-12-31: $19.9M2021-03-31: $20.9M2021-06-30: $23.8M2021-09-30: $16.1M2021-12-31: $41.3M
    the quarter ended 31 Dec 20217 earlier quartersnormal: $16.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  30. 27 Aug 2021Filings record

    A major agreement ended

  31. 15 Mar 2021Filings record

    Registered new securities for sale (S-1)

  32. 18 Dec 2020Filings record

    A major agreement ended

  33. 18 Nov 2020Filings record

    Registered new securities for sale (S-1)

  34. 13 Nov 2020Filings record

    Registered new securities for sale (S-1)

  35. 12 Nov 2020Filings record

    Registered new securities for sale (S-1)

  36. 2 Nov 2020Filings record

    Registered new securities for sale (S-1)

  37. 23 Oct 2020Filings record

    Registered new securities for sale (S-1)

  38. 14 Apr 2020Lobbying record

    NORDION, INC. (FKA NORDION (CANADA), INC.): new lobbying registration (VAN NESS FELDMAN, LLP) (dated 1 Mar 2020)

  39. 22 Oct 2019several at once

    filed a WARN layoff notice covering 37 workers within 30 days, while it reported $150K of lobbying spend for the quarter ended 30 Sep 2019, 2.1× the same quarter last year. Two unrelated kinds of activity within 21 days.

    See the evidence (2 changes)

    Layoff notices: WARN layoff notice became public on 1 Oct 2019

    Sotera Health filed a WARN layoff notice covering 37 workers within 30 days.

    Notices in the window
    1
    Workers named
    37
    Window
    1 Sep 2019 to 1 Oct 2019

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

    Lobbying: Lobbying spend jump became public on 17 Oct 2019

    Sotera Health reported $150K of lobbying spend for the quarter ended 30 Sep 2019, 2.1× the same quarter last year.

    This period
    $150K (the quarter ended 30 Sep 2019)
    Normal quarter (median of 8 earlier)
    $60K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +4.5
    Same quarter last year
    $70K
    History used
    1,278 days
    2017-09-30: $60K2017-12-31: $60K2018-03-31: $60K2018-06-30: $60K2018-09-30: $70K2018-12-31: $60K2019-03-31: $125K2019-06-30: $145K2019-09-30: $150K
    the quarter ended 30 Sep 20198 earlier quartersnormal: $60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  40. 17 Oct 2019Lobbying change

    reported $150K of lobbying spend for the quarter ended 30 Sep 2019, 2.1× the same quarter last year.

    Same quarter last year: $70K; its normal quarter is $60K.

    See the evidence
    This period
    $150K (the quarter ended 30 Sep 2019)
    Normal quarter (median of 8 earlier)
    $60K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +4.5
    Same quarter last year
    $70K
    History used
    1,278 days
    2017-09-30: $60K2017-12-31: $60K2018-03-31: $60K2018-06-30: $60K2018-09-30: $70K2018-12-31: $60K2019-03-31: $125K2019-06-30: $145K2019-09-30: $150K
    the quarter ended 30 Sep 20198 earlier quartersnormal: $60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

Showing the newest 40 of 51 entries; narrow the window or the kind of data to see older ones.

Not listed: 113 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001822479
Ticker
SHC
Domain
soterahealth.com
Employer name
Nelson Laboratories LLC, Sotera Health (2 unverified)
Fein
84-3877722 (1 unverified)
Hq location
OH|BROADVIEW HEIGHTS|44147 (1 unverified)
Name
Companhia Brasileira de Esterilização, DEROSS Holding B.V, Nelson Laboratories Bozeman, LLC, Nelson Laboratories Fairfield Holdings, LLC and 36 more
Uei
Y4SEUKNFMM95
  • DOL H-1B labor condition applications and PERM certifications10 data points16 Oct 2023 to 28 Apr 2025
  • Federal lobbying disclosures (LDA)8 records, 83 data points1 Feb 2016 to 30 Sep 2026
  • SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)103 records23 Oct 2020 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)465 data points31 Dec 2018 to 27 Oct 2026
  • SEC Form 4 insider transactions34 records, 56 data points24 Mar 2021 to 19 Aug 2026
  • FINRA short interest (twice monthly)425 data points30 Nov 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3014 data points20 Nov 2020 to 20 Nov 2026
  • USASpending.gov federal awards3 data points25 May 2024 to 25 May 2024
  • WARN layoff notices (state labor agencies)2 records, 6 data points30 Sep 2019 to 1 Jan 2023